Thermo Fisher Scientific (TMO) Capital Expenditures (2009 - 2026)

Thermo Fisher Scientific has reported Capital Expenditures for 18 years, with the latest figure at $450.0 million in Q2 2026.

• Capital Expenditures for Q2 2026 came in at $450.0 million, up 53.06% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 20.38% YoY), and the FY2025 annual result was $1.5 billion, up 8.93% from the prior year.
• Capital Expenditures advanced to $450.0 million in Q2 2026, from $376.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $640.0 million in Q2 2022 and troughed at $272.0 million in Q3 2024.
• A 5-year average of $415.2 million and a median of $404.5 million in 2023 frame the typical range for Capital Expenditures.
• The widest annual swing landed in 2023, when Capital Expenditures tumbled 43.87%; it then jumped 53.06% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $550.0 million in 2022, then retreated by 26.36% to $405.0 million in 2023, then climbed by 18.52% to $480.0 million in 2024, then slipped by 3.12% to $465.0 million in 2025, then dropped by 3.23% to $450.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $450.0 million in Q2 2026, $376.0 million in Q1 2026, and $465.0 million in Q4 2025.